资产管理业务方面，公司以全资子公司九安香港公司为主，以自有资金从事资产管理业务。截至2025年 半年末，公司多元化配置的资产组合中，固定收益类资产占比59.2%，公开市场权益占比26.2%，私募 股权占比12.6%，对冲基金占比2.0%。 中证报中证网讯(王珞)九安医疗（002432）近日发布的2025年半年度报告显示，上半年公司实现营业收 入7.65亿元；实现净利润9.2亿元，同比增长52.91%。 报告期内，公司的iHealth系列产品以其出色的市场表现和盈利能力，为公司收入和利润做出了重要贡 献。该系列产品的营业收入约6.01亿元人民币，展示了其市场竞争力和盈利能力。公司的试剂盒产品销 量情况良好，特别是在亚马逊平台上，在售价较市场同类产品居前列的同时，销量长期位居该品类的 Best Seller，显示了iHealth产品的市场认可度和品牌价值。 公司在智能助听器领域，拟推出的最新款AI智能助听器尚在研发过程中，该产品搭建全新的移动听力 计算架构，加持AI神经网络助听算法，通过全方位、多层次处理，确保用户可以在任何环境下都能享 受到清晰、自然的听觉体验。目前该项目正在持续稳步推进中，并计划在年内完成样机 ...

证券代码：002432 证券简称：九安医疗 天津九安医疗电子股份有限公司 投资者关系活动记录表 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 线上参与单位 | 网上业绩说明会：通过网络远程方式参加公司"2025 年半年度网上业 | | 名称及人员姓 | 绩说明会"的广大投资者。 | | 名 | 特定对象调研：具体参会机构清单，详见后附"特定调研对象清单"。 | | 时间 | 网上业绩说明会：2025 年 8 月 27 日 15：00-16：00 | | | 特定对象调研：2025 年 8 月 27 日 16：15-17：15 | | 方式 | 网上业绩说明会：网络远程文字方式 | | | 特定对象调研：电话会议方式 | | 上市公司接待 | 董事长、总经理：刘毅 先生 | | | 董事、副总经理：王湧 先生 | | | 董事、副总经理：丛明 先生 | | 人员姓名 | 独立董事：孙卫军 先生 | | | 董事会秘书：邬彤 先生 | | | 财务经理（代行 ...

融资净买入超1亿元的股票中，哪些兼具高成长和低估值？数据宝统计，按照半年报、业绩快报计算，2025年上半年净利 润同比增长超20%（含扭亏为盈），同时滚动市盈率低于30倍的个股有31只。 滚动市盈率最低的是物产中大，仅为8.93倍，公司是中国具有影响力的大宗商品供应链集成服务商之一，今年上半年实现 归母净利润20.4亿元，同比增长29.65%。报告期内，公司牵头攻关"深海海洋用拖拽声探电缆""新型耐低温聚氯乙烯弹性 体材料"等关键技术，替代进口依赖型产品。 九安医疗滚动市盈率为9.54倍，紧随其后。公司今年上半年实现归母净利润9.2亿元，同比增长52.91%。半年报显示，在 持续血糖监测领域，公司已完成多批次试生产，目前已在国内积极开展型检和临床相关工作，同时也在积极推进国外 CGM产品的研发工作。在智能助听器领域，公司拟推出的最新款AI智能助听器尚在研发过程中，该项目计划在年内完成 样机的制作和用户反馈的收集。 达仁堂滚动市盈率为9.56倍，今年上半年实现归母净利润19.28亿元，同比增长193.08%。报告期内，公司出售联营公司天 津史克12%的股权，实现处置收益15.4亿元，税后净利润13.1亿元。公司 ...

Core Insights - Company reported a significant increase in revenue and profit for the first half of 2025, with operating income reaching 765 million yuan and net profit growing by 52.91% year-on-year to 920 million yuan [1] Group 1: Financial Performance - The company achieved an operating income of 765 million yuan in the first half of 2025 [1] - Net profit attributable to shareholders was 920 million yuan, reflecting a year-on-year growth of 52.91% [1] - The basic earnings per share stood at 2.10 yuan [1] Group 2: Product and Brand Development - In the IVD sector, the global market is projected to reach 81 billion USD by the end of 2024, with the company's iHealth series products generating approximately 601 million yuan in revenue [2] - iHealth brand products, including IoT blood pressure monitors and thermometers, have consistently ranked as Best Sellers on Amazon in the U.S. [2] - The company is advancing its continuous glucose monitoring (CGM) products and AI smart hearing aids, with plans to complete prototype development and user feedback collection within the year [2] Group 3: Internet Healthcare Initiatives - The company's diabetes care business generated revenue of 50.26 million yuan, expanding its service coverage and patient base [3] - The "O+O" model for diabetes care is being promoted in approximately 50 cities and 424 hospitals in China, serving around 366,000 patients [3] - In the U.S., the company collaborates with about 74 clinics and 394 doctors, covering around 21,000 patients, supported by Medicare's payment policy for "internet + healthcare" services [3] Group 4: Strategic Investments and Future Outlook - The company is strategically investing in sectors such as hard technology, healthcare, artificial intelligence, biomanufacturing, new energy, and new materials [4] - Collaborations with universities like Tianjin University aim to support promising startup teams [4] - The company plans to continue focusing on healthcare and technology sectors, leveraging innovation as a core driver for future growth [4]

Group 1: Investment and Financing Activities - Weiming Shiguang completed a strategic round of financing of nearly 100 million RMB, with investments from L'Oréal Group and Naies Group, highlighting its leading position in the field of bioactive materials innovation [2] - Digital Light Chip recently completed a tens of millions RMB A+ round of financing, led by Guangdong Hengqin Shenhe Industrial Investment, to support ongoing chip research and design [3] - Xincheng Entertainment completed a tens of millions RMB A round of financing, with funds aimed at developing an AI content production engine and establishing an overseas operational center [3][4] - IMCOCO Group announced the completion of a Pre-A round financing of over 100 million RMB, with funds allocated for factory capacity expansion and global brand development [5] - Shandong Jinghu Technology completed a tens of millions RMB financing round to upgrade production equipment and expand capacity for high-end quartz crystal materials [6] - Airwallex completed a $300 million Series F financing, bringing its total funding to over $1.2 billion, with plans to expand its global financial service infrastructure [8] Group 2: Company Developments and Strategic Partnerships - Weiming Shiguang established a strategic partnership with L'Oréal Group to co-develop innovative bioactive ingredients and promote low-carbon biomanufacturing technology [2] - Xincheng Entertainment has set up six operational hubs in Southeast Asia and Europe, creating a network of creators across 20 countries [4] - Digital Light Chip focuses on silicon-based micro-display driver chip design, serving various applications including AR/VR and automotive projection [3] - Jinghu Technology specializes in high-performance quartz crystals, primarily used in 5G communication and aerospace applications [6] - Airwallex aims to optimize its software platform and support businesses in achieving borderless growth through its expanded financial services [8]

证券代码：002432 证券简称：九安医疗 天津九安医疗电子股份有限公司 投资者关系活动记录表 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 线上参与单位 | 年度暨 年一 网上业绩说明会：通过网络远程方式参加公司"2024 2025 | | 名称及人员姓 | 季度网上业绩说明会"的广大投资者。 | | 名 | 特定对象调研：具体参会机构清单，详见后附"特定调研对象清单"。 | | 时间 | 网上业绩说明会：2025 年 4 月 29 日 15：00-16：00 | | | 特定对象调研：2025 年 4 月 29 日 16：15-17：15 | | 方式 | 网上业绩说明会：网络远程文字方式 | | | 特定对象调研：电话会议方式 | | 上市公司接待 | 董事长、总经理：刘毅 先生 | | | 董事、副总经理：王湧 先生 | | | 董事、副总经理：丛明 先生 | | 人员姓名 | 独立董事：孙卫军 先生 | | | 董事会秘书：邬彤 先生 | | ...